Veterinary Pain Management Market Growth & Trends
The global veterinary pain management market size is expected to reach USD 3.82 billion in 2030 and is projected to grow at a CAGR of 6.80% from 2025 to 2030. The primary drivers of market growth include the advent of monoclonal antibodies in OA associated pain control, rising prevalence of diseases in animals such as osteoarthritis, rising pet ownership, increasing number of veterinarians, and increasing animal health expenditure. In May 2023, Zoetis’s Librela mAb received the U.S. FDA approval for use in dog OA pain control. Moreover, pet insurance adoption is increasing due to a number of factors, including pet humanization, a growing pet population, greater initiatives by major companies, and rising veterinary care expenses.
Increasing number of veterinarians is expected to fuel the market growth. For instance, according to AVMA, there were a total of 127,131 vet practitioners in the U.S. veterinarians are now better equipped with tools and knowledge to identify and address pain in animals, whether it's acute or chronic. Moreover, there’s a greater emphasis on educating veterinarians about recognizing and managing pain in animals. Veterinary schools are incorporating pain management into their curricula, and continuing education programs keep practicing veterinarians up-to-date on the latest techniques and medications. Overall, the increasing number of veterinarians driving the veterinary pain management market reflects a positive shift towards better care and understanding of animals' needs, aligning with the broader trend of humanizing pets and recognizing their emotional and physical well-being.
Veterinary pain management has become a crucial aspect of pet care, particularly with conditions such as cancer, where pain can be a significant symptom. With the increase in cancer cases among dogs, there's likely a corresponding increase in the demand for effective pain management solutions in veterinary practice. Approximately fifty percent of dogs over the age of ten develop cancer. Cancer in dogs occurs at a rate similar to that of humans. There are certain cancers that affect cats more frequently than dogs, like lymphoma. In order to help manage pain in dogs with cancer, veterinarians frequently combine pharmaceuticals, such as analgesics and anti-inflammatory medicines, with complementary therapies, such as acupuncture and physical therapy.
Furthermore, key mergers and acquisitions, regional expansions, product launches, etc., to increase their foothold in the market. For instance, in January 2024, Ceva acquired Scout Bio, a leading biotechnology firm specializing in advanced therapies for pets. This acquisition marks a substantial advancement for Ceva, granting access to groundbreaking treatments such as monoclonal antibodies and gene therapy aimed to tackle chronic pet diseases.
Request a free sample copy or view report summary: Veterinary Pain Management Market Report
Veterinary Pain Management Market Report Highlights
- The NSAIDs segment led the market with the largest revenue share of 85% in 2024. and is anticipated to grow at a lucrative CAGR over the forecast period
- Based on indication, the osteoarthritis (OA) segment led the market with the largest revenue share of 68.11%in 2024
- Based on animal, the production animals segment led the market with the largest with the largest revenue share of 64% in 2024.
- Based on route of administration, the oral segment led the market with the largest revenue share of 43.55% in 2024
- Based on mode of purchase, the prescription segment led the market with the largest revenue share of 84.05% in 2024
- Based on end use, the hospitals & clinics segment led the market with the largest revenue share of 82.49% in 2024
- North America dominated the veterinary pain management market with the largest revenue share of 39.56% in 2024
Access Press Release@ https://www.grandviewresearch.com/press-release/global-veterinary-pain-management-market
Veterinary Pain Management Market Segmentation
Grand View Research has segmented the global Veterinary Pain Management market report based on application, end use, and region:
Veterinary Pain Management Product Outlook (Revenue, USD Million, 2018 - 2030)
- NSAIDs
- Anesthetics
- Opioids
- Others
Veterinary Pain Management Indication Outlook (Revenue, USD Million, 2018 - 2030)
- Osteoarthritis
- Postoperative Pain
- Others
Veterinary Pain Management Animal Outlook (Revenue, USD Million, 2018 - 2030)
- Production Animals
- Companion Animals
Veterinary Pain Management Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
- Parenteral
- Oral
- Topical
Veterinary Pain Management Mode of Purchase Outlook (Revenue, USD Million, 2018 - 2030)
- Prescription
- OTC
Veterinary Pain Management End Use Outlook (Revenue, USD Million, 2018 - 2030)
- Hospitals & Clinics
- Others
Veterinary Pain Management Regional Outlook (Revenue, USD Million, 2018 - 2030)
- North America
- US.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Norway
- Sweden
- Denmark
- Asia Pacific
- Japan
- China
- India
- South Korea
- Australia
- Thailand
- Latin America
- Brazil
- Argentina
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
List of Key Players in Veterinary Pain Management Market
- Boehringer Ingelheim
- Vetoquinol
- Ceva Animal Health, Llc
- Chanelle Pharma (Exponent)
- Elanco
- Dechra Pharmaceuticals Plc (Eqt)
- Zoetis
- Merck & Co., Inc.
- Norbrook
- Assisi (Wind Point Partners)
About Grand View Research
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.
No comments:
Post a Comment